INTERLEUKIN 2 RECEPTOR INDUCERS: PATHOLOGICAL ROLES IN ADULT T CELL LEUKEMIA NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


INTERLEUKIN 2 RECEPTOR INDUCERS: PATHOLOGICAL ROLES IN ADULT T CELL LEUKEMIA

Interleukin 2. Smith KA, ed. New York, Academic, p. 197-222, 1988.. Unique Identifier : AIDSLINE ICDB/89656589
Yodoi J; Tagaya Y; Maeda M; Inst. for Immunology, Faculty of Medicine, Kyoto Univ., Yoshida,; Sakyo-ku, Kyoto 606, Japan


Abstract: The functional state and expression of hormone and cytokine receptors are regulated by the specific ligands for the respective receptors and by unrelated mediators. Such a regulatory circuit in the interleukin 2 (IL-2)/IL-2 receptor (IL-2R) system is discussed and its key role in the immune system relative to T-cell leukemogenesis by human T-lymphotropic virus (HTLV)-I is considered. Topics include studies of IL-2R and adult T-cell leukemia (ATL), properties of human IL-2R protein, cloning of IL-2R gene, humoral control of IL-2R expression, abnormal regulation of IL-2R expression in ATL, ATL-derived factor (ADF) inducing IL-2R expression, a stepwise progression model of IL-2-dependent and -independent ATL, and possible roles of IL-2R dysregulation in ATL. HTLV-I+ leukemic T cells and T-cell lines from patients with ATL continuously expressed IL-2R without significant production of IL-2. The lack of downregulation of IL-2R by anti-Tac monoclonal antibody recognizing IL-2R suggested the presence of an abnormality in the IL-2R system in ATL, but there was no aberration in the size and charge of Tac antigen unique to ATL. The cDNA coding for Tac antigen also coded for IL-2R, proving that Tac epitope is expressed on the IL-2R molecule. In ATL cell lines and in fresh leukemic cells of ATL, however, there was no abnormality of the structural gene for IL-2R, despite the continued elevation of mRNA for IL-2R. Many HTLV-I+ T4+ T-cell lines constitutively produce the non-IL-2 lymphokine ADF, which induced the expression of the high-affinity IL-2R on a variety of cells, including HTLV-I+ T cells and the HTLV-I- natural-killer-like leukemic cell line cells (YT cells). Expression of IL-2R on YT cells as induced by a variety of agents, including ADF, IL-1s, phorbol esters, and forskolin which is a direct activator of adenylate cyclase, but not by T-cell mitogens or IL-2. Purified ADF has a mol wt of about 13,000-17,000 on gel filtration and 15,000-20,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and is an acid protein with a pI of 4.5-5.5. ADF activates expression of IL-2R and its gene by enhancing the transcription of IL-2R mRNA. There are functional antigenic differences between ADF and other IL-2R-inducing cytokines such as IL-1s. Constitutively expressed IL-2R in leukemogenesis actually may be involved in the neoplastic growth of ATL cells or the IL-2R on ATL cells may play a key role in leukemogenesis, but not be involved in the continued proliferation of leukemic cells. (74 Refs)
Keywords: Animal Cell Line Cloning, Molecular Gene Expression Regulation Human Interleukin-2/GENETICS/*PHYSIOLOGY Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/GENETICS/ PHYSIOPATHOLOGY Leukemia, T-Cell/GENETICS/*PHYSIOPATHOLOGY Ligands Lymphokines/PHYSIOLOGY Models, Biological Neoplasm Proteins/GENETICS/PHYSIOLOGY Receptors, Interleukin-2/DRUG EFFECTS/GENETICS/*PHYSIOLOGY MONOGRAPH REVIEW REVIEW, TUTORIAL

KWDanimalcelllinecloning,moleculargeneexpressionregulationhumaninterleukin-2/genetics/KWDphysiologyleukemia-lymphoma,t-cell,acute,htlv-i-associated/genetics/physiopathologyleukemia,t-cell/genetics/KWDphysiopathologyligandslymphokines/physiologymodels,biologicalneoplasmproteins/genetics/physiologyreceptors,interleukin-2/drugeffects/genetics/KWDphysiologymonographreviewreview,tutorial
891130
M89B0598


Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .